News Releases

IBBR Request for Proposals (RFP): GMP Biomanufacturing Facility Available - Rockville, Maryland, USA


(Rockville, August 19, 2019) - The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Point of Concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research... Read More

IBBR Collaborates with Integrated BioTherapeutics to Advance a Novel Approach to Treating Infectious Disease


A single therapeutic simultaneously targets bacteria and neutralizes toxins

(Rockville, MD, August 14, 2019) IBBR Fellow Dr. Daniel Nelson (Associate Professor, UMCP Department of Veterinary Medicine) and collaborators at Integrated BioTherapeutics and George Mason University recently received a $3M Phase II STTR award from the NIH to advance their novel immunotherapeutic into non-human primates and to optimize a cell line for biomanufacturing the drug.

IBBR Researchers Awarded $1M from DTRA to Develop Portable Medical Sensors


Redox information may hold key to rapidly diagnosing disease

(Rockville, MD, July 15, 2019) IBBR researchers recently received $1M from the Defense Threat Reduction Agency (DTRA, part of the US Department of Defense) to advance their work developing wearable sensors that measure biochemical information to diagnose disease. IBBR Fellow Dr. Gregory Payne (Research Professor, IBBR) is principal investigator on the award.

IBBR Investigator to Lead $3.5M NIH-Funded Project to Study Immune Response to HIV-1


Funding will support novel vaccine design aimed at improving protective antibody responses

(Rockville, MD, April 24, 2019) Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $3.5M from the National Institutes of Health (NIH) to advance understanding of the complex process by which the immune system produces highly specialized antibodies. 

IBBR Awarded NIH Grant to Investigate T Cell Biology Toward Development of Biotherapeutics


Findings may show how immune checkpoint LAG3 can be exploited to fight disease

(Rockville, MD, January 31, 2019) A team of investigators from the Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh recently received a $3.6M National Institutes of Health award to expand the scope of their T cell research involving LAG3 -- a well-known inhibitory receptor on T cells implicated in various cancers, as well as in the chronic infections associated with malaria and HIV.

IBBR Investigator to Lead $3.9M NIH-Funded Project to Develop Next-Generation HIV-1 Immunotherapy Agents


Multi-specific anti-HIV antibodies that neutralize almost all circulating HIV-1 viruses will be optimized to target persistent infection

(Rockville, MD, November 20, 2018) IBBR researchers recently received $3.9 million from the National Institutes of Health (NIH) to develop a multi-specific, single agent antibody therapeutic against HIV-1 to block virus infection and to clear the reservoir of HIV-infected cells from the body. 

IBBR Receives $1.2M NIH Award to Develop 3D Modeling Tool That Could Lead to New Immunotherapies


New computational tool supports the engineering and development of cancer immunotherapies by predicting how T cell receptors recognize and bind to their targets

(Rockville, MD, October 3, 2018)  The Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $1.2M National Institute of Health (NIH) grant to generate a robust modeling and design framework to predict the structures of T cell receptors (TCRs) from sequence, model antigen recognition, and design new TCRs with desired targeting capabilities that can be applied in therapies against... Read More

IBBR Researcher, Dr. Alexander Andrianov, Receives Funding for Two Collaborations


Collaborations will explore using two novel types of biofunctional synthetic macromolecules of the polyphosphazene (PPZ) family for exciting and very different applications. 

(Rockville, MD, October 17, 2018) Dr. Andrianov and his collaborator Dr. Svetlana Sukhishvili, of Texas A&M University, have demonstrated that layer-by-layer (LbL) assembly of amphiphilic (containing both hydrophilic and hydrophobic components) PPZs can be employed to create nano-structured fluorinated coatings that display superior biocompatibility. In another... Read More

Targeting HIV: Moving closer to a potential cure


Tri-specific antibody targets and neutralizes 99.5% of HIV-1 virus strains

(Rockville, MD, March 13, 2018) A team of researchers at IBBR, led by Dr. Yuxing Li, Associate Professor at the University of Maryland School of Medicine, Baltimore, and Principal Investigator at the Institute for Bioscience and Biotechnology Research (IBBR), Rockville, is showing how engineered multi-specific antibodies appear to be highly effective at preventing infection across a broad range of HIV-1 virus strains.

IBBR awarded DOE grant to investigate how to protect an emerging biofuel crop from disease


UMD researchers work to defend poplar trees – a promising resource for renewable and sustainable energy – from leaf rust and other diseases

(Rockville, MD, January 29, 2018)  The Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $1.1M U.S. Department of Energy grant to elucidate the mechanism of rust pathogenesis in poplar in an effort to engineer durable resistance for this important, second generation biofuel crop.  The collaborative, multidisciplinary research is led by Dr. Edward Eisenstein, IBBR Fellow and Associate Professor,... Read More